Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
Joseph Turow, PhD, Robert Gellman, JD, and Judith Turow, MD
Health marketers use a number of means to collect information about consumers, which when combined with health record information, could constitute a violation of patient privacy.
When evaluating the developments and complications of a marginally viable premature infant, physicians and parents must work together to decide on treatment that is in the infant’s best interest.
Physicians need to be aware of and guard against the liability risks of having nonphysician clinicians provide services that do not meet the standard of care of the practice due to the staff member's inadequate experience or supervision.
A physician defends her position that children should only participate in clinical trials when they have child assent and the parents also have been educated about the purpose of the research when there is no direct benefit to the child.
Physicians should be aware of the level of emotional distress and suffering that a patient is experiencing as a result of his or her illness and incorporate that into the patient's treatment plan.
Bioethicist Bruce Jennings examines the changing role of physicians in end-of-life care, from paternalistic decision maker to advisor-technician and half-way back.